Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Flex Pharma (FLKS) Share Price

Headlines about Flex Pharma (NASDAQ:FLKS) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Flex Pharma earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 48.3036208904814 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Flex Pharma (NASDAQ:FLKS) traded down 2.78% during midday trading on Friday, reaching $3.50. 67,358 shares of the company were exchanged. The stock’s market capitalization is $60.50 million. The firm’s 50-day moving average price is $3.73 and its 200 day moving average price is $3.88. Flex Pharma has a 52-week low of $3.01 and a 52-week high of $12.68.

Flex Pharma (NASDAQ:FLKS) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.12. Flex Pharma had a negative net margin of 2,410.97% and a negative return on equity of 64.15%. The business had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.46 million. Equities analysts predict that Flex Pharma will post ($2.42) earnings per share for the current year.

A number of equities analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Flex Pharma from a “sell” rating to a “hold” rating in a research report on Monday, August 7th. Jefferies Group LLC cut their target price on shares of Flex Pharma from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, May 4th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $15.40.

TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at

Flex Pharma Company Profile

Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.

Insider Buying and Selling by Quarter for Flex Pharma (NASDAQ:FLKS)

What are top analysts saying about Flex Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Flex Pharma Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit